Dendrimers as potential therapeutic tools in HIV inhibition

Molecules

Volumn 18, Issue 7, 2013, Pages 7912-7929

  Peng, Jianqing ^a   Wu, Zhenghong ^a   Qi, Xiaole ^a   Chen, Yi ^a   Li, Xiangbo ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

CD4; Dendrimer; Dendriplex; Gp121; HIV

Indexed keywords

CD4 ANTIGEN; DENDRIMER; GLYCOPROTEIN GP 120;

CHEMISTRY; DRUG EFFECT; GENE THERAPY; GENE VECTOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; PATHOGENICITY; REVIEW; VIROLOGY; DRUG EFFECTS; HIV INFECTIONS;

ANTIGENS, CD4; DENDRIMERS; GENETIC THERAPY; GENETIC VECTORS; HIV; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS;

EID: 84880816233     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules18077912     Document Type: Review

References (67)

1. UNAIDS. World Aids Day Report; UNAIDS BerlinGeneva: Geneva, Swizerland, 2012.
2. De Clercq, E. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 1995, 8, 200-239.
3. Fréchet, J.M.; Tomalia, D.A. Dendrimers and Other Dendritic Polymers; Wiley: New York, NY, USA, 2001.
4. Jiang, Y.-H.; Emau, P.; Cairns, J.S.; Flanary, L.; Morton, W.R.; McCarthy, T.D.; Tsai, C.-C. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89. 6P in macaques. AIDS Res. Hum. Retroviruses 2005, 21, 207-213.
5. Svenson, S.; Tomalia, D.A. Dendrimers in biomedical applications- Reflections on the field. Adv. Drug Deliv. Rev. 2005, 57, 2106-2129.
6. D'Emanuele, A.; Attwood, D. Dendrimer-Drug interactions. Adv. Drug. Deliv. Rev. 2005, 57, 2147-2162.
7. Witvrouw, M.; Fikkert, V.; Pluymers, W.; Matthews, B.; Mardel, K.; Schols, D.; Raff, J.; Debyser, Z.; De Clercq, E.; Holan, G. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle. Mol. Pharmacol. 2000, 58, 1100-1108.
8. Tyssen, D.; Henderson, S.A.; Johnson, A.; Sterjovski, J.; Moore, K.; La, J.; Zanin, M.; Sonza, S.; Karellas, P.; Giannis, M.P. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS One 2010, 5, e12309.
9. Telwatte, S.; Moore, K.; Johnson, A.; Tyssen, D.; Sterjovski, J.; Aldunate, M.; Gorry, P.R.; Ramsland, P.A.; Lewis, G.R.; Paull, J.R. Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. Antiviral Res. 2011, 90, 195-199.
10. Chonco, L.; Pion, M.; Vacas, E.; Rasines, B.; Maly, M.; Serramía, M.; López-Fernández, L.; De la Mata, J.; Alvarez, S.; Gómez, R. Carbosilane dendrimer nanotechnology outlines of the broad HIV blocker profile. J. Control Release 2012, 161, 949-958.
11. Galan, M.; Sanchez-Rodriguez, J.; Cangiotti, M.; Garcia-Gallego, S.; Jimenez, J.; Gomez, R.; Ottaviani, M.; Munoz-Fernandez, M.; de la Mata, F. Antiviral Properties Against HIV of Water Soluble Copper Carbosilane Dendrimers and their EPR Characterization. Curr. Med. Chem. 2012, 19, 4984-4994.
12. Kensinger, R.D.; Catalone, B.J.; Krebs, F.C.; Wigdahl, B.; Schengrund, C.-L. Novel polysulfated galactose-derivatized dendrimers as binding antagonists of human immunodeficiency virus type 1 infection. Antimicrob. Agents Chemother. 2004, 48, 1614-1623.
13. Han, S.; Yoshida, D.; Kanamoto, T.; Nakashima, H.; Uryu, T.; Yoshida, T. Sulfated oligosaccharide cluster with polylysine core scaffold as a new anti-HIV dendrimer. Carbohydr. Polym. 2010, 80, 1111-1115.
14. Han, S.; Kanamoto, T.; Nakashima, H.; Yoshida, T. Synthesis of a new amphiphilic glycodendrimer with antiviral functionality. Carbohydr. Polym. 2012, 90, 1061-1068.
15. Rosa Borges, A.; Wieczorek, L.; Johnson, B.; Benesi, A.J.; Brown, B.K.; Kensinger, R.D.; Krebs, F.C.; Wigdahl, B.; Blumenthal, R.; Puri, A. Multivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1. Virology 2010, 408, 80-88.
16. Doménech, R.; Abian, O.; Bocanegra, R.; Correa, J.; Sousa-Herves, A.; Riguera, R.; Mateu, M.G.; Fernandez-Megia, E.; Velázquez-Campoy, A. n.; Neira, J.L. Dendrimers as potential inhibitors of the dimerization of the capsid protein of HIV-1. Biomacromolecules 2010, 11, 2069-2078.
17. Zhao, H.; Li, J.; Xi, F.; Jiang, L. Polyamidoamine dendrimers inhibit binding of Tat peptide to TAR RNA. FEBS Lett. 2004, 563, 241-245.
18. Wang, W.; Guo, Z.; Chen, Y.; Liu, T.; Jiang, L. Influence of Generation 2-5 of PAMAM Dendrimer on the Inhibition of Tat Peptide/TAR RNA Binding in HIV-1 Transcription. Chem. Biol. Drug. Des. 2006, 68, 314-318.
19. Wyatt, R.; Sodroski, J. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 1998, 280, 1884-1888.
20. McCarthy, T.D.; Karellas, P.; Henderson, S.A.; Giannis, M.; O'Keefe, D.F.; Heery, G.; Paull, J.R.; Matthews, B.R.; Holan, G. Dendrimers as drugs: Discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2005, 2, 312-318.
21. Bernstein, D.; Stanberry, L.; Sacks, S.; Ayisi, N.; Gong, Y.; Ireland, J.; Mumper, R.; Holan, G.; Matthews, B.; McCarthy, T. Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob. Agents Chemother. 2003, 47, 3784-3788.
22. Dezzutti, C.S.; James, V.N.; Ramos, A.; Sullivan, S.T.; Siddig, A.; Bush, T.J.; Grohskopf, L.A.; Paxton, L.; Subbarao, S.; Hart, C.E. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob. Agents Chemother. 2004, 48, 3834-3844.
23. Rupp, R.; Rosenthal, S.L.; Stanberry, L.R. VivaGel®(SPL7013 Gel): A candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int. J. Nanomed. 2007, 2, 561.
24. Cohen, C.R.; Brown, J.; Moscicki, A.-B.; Bukusi, E.A.; Paull, J.R.; Price, C.F.; Shiboski, S. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days. PLoS One 2011, 6, e16258.
25. Price, C.F.; Tyssen, D.; Sonza, S.; Davie, A.; Evans, S.; Lewis, G.R.; Xia, S.; Spelman, T.; Hodsman, P.; Moench, T.R. SPL7013 Gel (VivaGel®) Retains Potent HIV-1 and HSV-2 Inhibitory Activity following Vaginal Administration in Humans. PLoS One 2011, 6, e24095.
26. Harouse, J.M.; Collman, R.G.; Gonzalez-Scarano, F. Human immunodeficiency virus type 1 infection of SK-N-MC cells: domains of gp120 involved in entry into a CD4-negative, galactosyl ceramide/3'sulfo-galactosyl ceramide-positive cell line. J. Virol. 1995, 69, 7383-7390.
27. Yahi, N.; Baghdiguian, S.; Moreau, H.; Fantini, J. Galactosyl ceramide (or a closely related molecule) is the receptor for human immunodeficiency virus type 1 on human colon epithelial HT29 cells. J. Virol. 1992, 66, 4848-4854.
28. Popik, W.; Alce, T.M.; Au, W.-C. Human immunodeficiency virus type 1 uses lipid raft-colocalized CD4 and chemokine receptors for productive entry into CD4+ T cells. J. Virol. 2002, 76, 4709-4722.
29. Bhat, S.; Spitalnik, S.L.; Gonzalez-Scarano, F.; Silberberg, D.H. Galactosyl ceramide or a derivative is an essential component of the neural receptor for human immunodeficiency virus type 1 envelope glycoprotein gp120. Proc. Natl. Acad. Sci. USA 1991, 88, 7131-7134.
30. Pérez-Anes, A.; Stefaniu, C.; Moog, C.; Majoral, J.-P.; Blanzat, M.; Turrin, C.-O.; Caminade, A.-M.; Rico-Lattes, I. Multivalent catanionic GalCer analogs derived from first generation dendrimeric phosphonic acids. Bioorg. Med. Chem. 2010, 18, 242-248.
31. Lundquist, J.J. The cluster glycoside effect. Chem Rev. 2002, 102, 555-578.
32. Katsuraya, K.; Ikushima, N.; Takahashi, N.; Shoji, T.; Nakashima, H.; Yamamoto, N.; Yoshida, T.; Uryu, T. Synthesis of sulfated alkyl malto-and laminara-oligosaccharides with potent inhibitory effects on AIDS virus infection. Carbohydr. Res. 1994, 260, 51-61.
33. Hug, P.; Lin, H.-M.J.; Korte, T.; Xiao, X.; Dimitrov, D.S.; Wang, J.M.; Puri, A.; Blumenthal, R. Glycosphingolipids promote entry of a broad range of human immunodeficiency virus type 1 isolates into cell lines expressing CD4, CXCR4, and/or CCR5. J. Virol. 2000, 74, 6377-6385.
34. Puri, A.; Hug, P.; Jernigan, K.; Barchi, J.; Kim, H.-Y.; Hamilton, J.; Wiels, J.; Murray, G.J.; Brady, R.O.; Blumenthal, R. The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein. Proc. Natl. Acad. Sci. USA 1998, 95, 14435-14440.
35. Puri, A.; Hug, P.; Jernigan, K.; Rose, P.; Blumenthal, R. Role of glycosphingolipids in HIV-1 entry: requirement of globotriosylceramide (Gb3) in CD4/CXCR4-dependent fusion. Biosci. Rep. 1999, 19, 317-325.
36. Geijtenbeek, T.B.; van Kooyk, Y. Pathogens target DC-SIGN to influence their fate DC-SIGN functions as a pathogen receptor with broad specificity. APMIS 2003, 111, 698-714.
37. Kooyk, Y.V.; Appelmelk, B.; Geijtenbeek, T.B. A fatal attraction:Mycobacterium tuberculosis and HIV-1 target DC-SIGN to escape immune surveillance. Trends Mol. Med. 2003, 9, 153-159.
38. Lozach, P.-Y.; Amara, A.; Bartosch, B.; Virelizier, J.-L.; Arenzana-Seisdedos, F.; Cosset, F.-L.; Altmeyer, R. C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J. Biol. Chem. 2004, 279, 32035-32045.
39. Doores, K.J.; Bonomelli, C.; Harvey, D.J.; Vasiljevic, S.; Dwek, R.A.; Burton, D.R.; Crispin, M.; Scanlan, C.N. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc. Natl. Acad. Sci. USA 2010, 107, 13800-13805.
40. Christopher, G. Selection of a synthetic glycan oligomer from a library of DNA-templated fragments against DC-SIGN and inhibition of HIV gp120 binding to dendritic cells. Chem. Commun. (Camb.) 2011, 47, 9321-9323.
41. Hamy, F.; Brondani, V.; Flörsheimer, A.; Stark, W.; Blommers, M.J.; Klimkait, T. A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition. Biochemistry 1998, 37, 5086-5095.
42. Dayton, A.I.; Sodroski, J.G.; Rosen, C.A.; Goh, W.C.; Haseltine, W.A. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 1986, 44, 941-947.
43. Zhao, H.; Dai, D.; Li, J.; Chen, Y.; Jiang, L. Quantitative study of HIV-1 Tat peptide and TAR RNA interaction inhibited by poly (allylamine hydrochloride). Biochem. Biophys. Res. Commun. 2003, 312, 351-354.
44. Asaftei, S.; De Clercq, E. "Viologen" Dendrimers as Antiviral Agents: The effect of charge number and distance. J. Med. Chem. 2010, 53, 3480-3488.
45. McGann, K.A.; Collman, R.; Kolson, D.L.; Gonzalez-Scarano, F.; Coukos, G.; Coutifaris, C.; Strauss, J.F.; Nathanson, N. Human immunodeficiency virus type 1 causes productive infection of macrophages in primary placental cell cultures. J. Infect. Dis. 1994, 169, 746-753.
46. Auger, M.; Ross, J.; Lewis, C.; McGee, J. The Natural Immune System: The Macrophage; Oxford University Press: New York, NY, USA, 1992.
47. Gordon, S. Mononuclear phagocytes in immune defence. Immunology 2001, 6, 147-162.
48. Lee, Y.C.; Townsend, R.; Hardy, M.R.; Lönngren, J.; Arnarp, J.; Haraldsson, M.; Lönn, H. Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin. Dependence on fine structural features. J. Biol. Chem. 1983, 258, 199-202.
49. Bhadra, D.; Yadav, A.; Bhadra, S.; Jain, N. Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. Int. J. Pharm. 2005, 295, 221-233.
50. Dutta, T.; Agashe, H.B.; Garg, M.; Balasubramanium, P.; Kabra, M.; Jain, N.K. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro: Research Paper. J. Drug Target. 2007, 15, 89-98.
51. Dutta, T.; Jain, N.K. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim. Biophys. Acta. 2007, 1770, 681-686.
52. Vinogradov, S.V.; Poluektova, L.Y.; Makarov, E.; Gerson, T.; Senanayake, M.T. Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity. Antivir. Chem. Chemother. 2010, 21, 1.
53. Buckley, D.L.; Corson, T.W.; Aberle, N.; Crews, C.M. HIV protease-mediated activation of sterically capped proteasome inhibitors and substrates. J. Am. Chem. Soc. 2010, 133, 698-700.
54. Pion, M.; Serramia, M.J.; Diaz, L.; Bryszewska, M.; Gallart, T.; García, F.; Gómez, R.; de la Mata, F.J.; Muñoz-Fernandez, M.Á. Phenotype and functional analysis of human monocytes-derived dendritic cells loaded with a carbosilane dendrimer. Biomaterials 2010, 31, 8749-8758.
55. Ionov, M.; Ciepluch, K.; Klajnert, B.; Glińska, S.; Gomez-Ramirez, R.; de la Mata, F.J.; Munoz-Fernandez, M.A.; Bryszewska, M. Complexation of HIV derived peptides with carbosilane dendrimers. Colloids Surf. B Biointerfaces. 2012, 101, 236-242.
56. Rinaldo, C., Dendritic cell-based human immunodeficiency virus vaccine. J. Intern. Med. 2009, 265, 138-158.
57. Rayburn, E.; Wang, W.; Zhang, R.; Wang, H. Antisense approaches in drug discovery and development. In Prog Drug Res.; Springer: Basel, Swizerland, 2005.
58. Chonco, L.; Bermejo-Martín, J.F.; Ortega, P.; Shcharbin, D.; Pedziwiatr, E.; Klajnert, B.; de la Mata, F.J.; Eritja, R.; Gómez, R.; Bryszewska, M. Water-soluble carbosilane dendrimers protect phosphorothioate oligonucleotides from binding to serum proteins. Org. Biomol. Chem. 2007, 5, 1886-1893.
59. Gonzalo, T.; Clemente, M.I.; Chonco, L.; Weber, N.D.; Díaz, L.; Serramía, M.J.; Gras, R.; Ortega, P.; de la Mata, F.J.; Gómez, R. Gene Therapy in HIV-Infected Cells to Decrease Viral Impact by Using an Alternative Delivery Method. ChemMedChem. 2010, 5, 921-929.
60. De Las Cuevas, N.; Garcia-Gallego, S.; Rasines, B.; de la Mata, F.; G Guijarro, L.; Munoz-Fernandez, M.; Gomez, R. In Vitro Studies of Water-Stable Cationic Carbosilane Dendrimers As Delivery Vehicles for Gene Therapy Against HIV and Hepatocarcinoma. Curr Med. Chem. 2012, 19, 5052-5061.
61. Pedziwiatr-Werbicka, E.; Shcharbin, D.; Maly, J.; Maly, M.; Zaborski, M.; Gabara, B.; Ortega, P.; de la Mata, F.J.; Gomez, R.; Munoz-Fernandez, M.A. Carbosilane Dendrimers are a Non-Viral Delivery System for Antisense Oligonucleotides: Characterization of Dendriplexes. J. Biomed. Nanotechnol. 2012, 8, 57-73.
62. Shcharbin, D.; Pedziwiatr, E.; Nowacka, O.; Kumar, M.; Zaborski, M.; Ortega, P.; Javier de la Mata, F.; Gómez, R.; Muñoz-Fernandez, M.A.; Bryszewska, M. Carbosilane dendrimers NN8 and NN16 form a stable complex with siGAG1. Colloids Surf. B Biointerfaces. 2011, 83, 388-391.
63. Weber, N.; Ortega, P.; Clemente, M.I.; Shcharbin, D.; Bryszewska, M.; de la Mata, F.J.; Gómez, R.; Muñoz-Fernández, M. Characterization of carbosilane dendrimers as effective carriers of siRNA to HIV-infected lymphocytes. J. Control Release 2008, 132, 55-64.
64. Jiménez, J.L.; Clemente, M.I.; Weber, N.D.; Sanchez, J.; Ortega, P.; de la Mata, F.J.; Gómez, R.; García, D.; López- Fernández, L.A.; Muñoz-Fernández, M.Á. Carbosilane dendrimers to transfect human astrocytes with small interfering RNA targeting human immunodeficiency virus. BioDrugs 2010, 24, 331-343.
65. Szewczyk, M.; Drzewinska, J.; Dzmitruk, V.; Shcharbin, D.; Klajnert, B.; Appelhans, D.; Bryszewska, M. Stability of Dendriplexes Formed by Anti-HIV Genetic Material and Poly (propylene imine) Dendrimers in the Presence of Glucosaminoglycans. J. Phys. Chem. B 2012, 116, 14525-14532.
66. Zhou, J.; Neff, C.P.; Liu, X.; Zhang, J.; Li, H.; Smith, D.D.; Swiderski, P.; Aboellail, T.; Huang, Y.; Du, Q. Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol. Ther. 2011, 19, 2228-2238.
67. Briz, V.; Serramia, M.; Madrid, R.; Hameau, A.; Caminade, A.-M.; Majoral, J.; Munoz-Fernandez, M. Validation of a Generation 4 Phosphorus-Containing Polycationic Dendrimer for Gene Delivery Against HIV-1. Curr. Med. Chem. 2012, 19, 5044-5051.